168 related articles for article (PubMed ID: 32029828)
1. Identification of gene signature for treatment response to guide precision oncology in clear-cell renal cell carcinoma.
D'Costa NM; Cina D; Shrestha R; Bell RH; Lin YY; Asghari H; Monjaras-Avila CU; Kollmannsberger C; Hach F; Chavez-Munoz CI; So AI
Sci Rep; 2020 Feb; 10(1):2026. PubMed ID: 32029828
[TBL] [Abstract][Full Text] [Related]
2. Roles of the Dynamic Tumor Immune Microenvironment in the Individualized Treatment of Advanced Clear Cell Renal Cell Carcinoma.
Lin E; Liu X; Liu Y; Zhang Z; Xie L; Tian K; Liu J; Yu Y
Front Immunol; 2021; 12():653358. PubMed ID: 33746989
[TBL] [Abstract][Full Text] [Related]
3. Mutations in renal cell carcinoma.
D'Avella C; Abbosh P; Pal SK; Geynisman DM
Urol Oncol; 2020 Oct; 38(10):763-773. PubMed ID: 30478013
[TBL] [Abstract][Full Text] [Related]
4. Clear-cell Renal Cell Carcinoma: Molecular Characterization of IMDC Risk Groups and Sarcomatoid Tumors.
Verbiest A; Renders I; Caruso S; Couchy G; Job S; Laenen A; Verkarre V; Rioux-Leclercq N; Schöffski P; Vano Y; Elaidi RT; Lerut E; Albersen M; Oudard S; Fridman WH; Sautès-Fridman C; Albigès L; Wozniak A; Zucman-Rossi J; Beuselinck B
Clin Genitourin Cancer; 2019 Oct; 17(5):e981-e994. PubMed ID: 31229459
[TBL] [Abstract][Full Text] [Related]
5. Exploration of immune-related genes in high and low tumor mutation burden groups of chromophobe renal cell carcinoma.
Li L; Chen X; Hao L; Chen Q; Liu H; Zhou Q
Biosci Rep; 2020 Jul; 40(7):. PubMed ID: 32662515
[TBL] [Abstract][Full Text] [Related]
6. Endogenous retrovirus expression is associated with response to immune checkpoint blockade in clear cell renal cell carcinoma.
Panda A; de Cubas AA; Stein M; Riedlinger G; Kra J; Mayer T; Smith CC; Vincent BG; Serody JS; Beckermann KE; Ganesan S; Bhanot G; Rathmell WK
JCI Insight; 2018 Aug; 3(16):. PubMed ID: 30135306
[TBL] [Abstract][Full Text] [Related]
7. Using Genomic and Transcriptome Analyses to Identify the Role of the Oxidative Stress Pathway in Renal Clear Cell Carcinoma and Its Potential Therapeutic Significance.
Che X; Qi X; Xu Y; Wang Q; Wu G
Oxid Med Cell Longev; 2021; 2021():5561124. PubMed ID: 34721758
[TBL] [Abstract][Full Text] [Related]
8. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
9. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
10. Molecular subtypes of clear cell renal cell carcinoma are associated with sunitinib response in the metastatic setting.
Beuselinck B; Job S; Becht E; Karadimou A; Verkarre V; Couchy G; Giraldo N; Rioux-Leclercq N; Molinié V; Sibony M; Elaidi R; Teghom C; Patard JJ; Méjean A; Fridman WH; Sautès-Fridman C; de Reyniès A; Oudard S; Zucman-Rossi J
Clin Cancer Res; 2015 Mar; 21(6):1329-39. PubMed ID: 25583177
[TBL] [Abstract][Full Text] [Related]
11. A four-gene signature predicts survival in clear-cell renal-cell carcinoma.
Dai J; Lu Y; Wang J; Yang L; Han Y; Wang Y; Yan D; Ruan Q; Wang S
Oncotarget; 2016 Dec; 7(50):82712-82726. PubMed ID: 27779101
[TBL] [Abstract][Full Text] [Related]
12. Pro-angiogenic gene expression is associated with better outcome on sunitinib in metastatic clear-cell renal cell carcinoma.
Beuselinck B; Verbiest A; Couchy G; Job S; de Reynies A; Meiller C; Albersen M; Verkarre V; Lerut E; Méjean A; Patard JJ; Laguerre B; Rioux-Leclercq N; Schöffski P; Oudard S; Zucman-Rossi J
Acta Oncol; 2018 Apr; 57(4):498-508. PubMed ID: 29095068
[TBL] [Abstract][Full Text] [Related]
13. Prognostic Value of a Long Non-coding RNA Signature in Localized Clear Cell Renal Cell Carcinoma.
Qu L; Wang ZL; Chen Q; Li YM; He HW; Hsieh JJ; Xue S; Wu ZJ; Liu B; Tang H; Xu XF; Xu F; Wang J; Bao Y; Wang AB; Wang D; Yi XM; Zhou ZK; Shi CJ; Zhong K; Sheng ZC; Zhou YL; Jiang J; Chu XY; He J; Ge JP; Zhang ZY; Zhou WQ; Chen C; Yang JH; Sun YH; Wang LH
Eur Urol; 2018 Dec; 74(6):756-763. PubMed ID: 30143382
[TBL] [Abstract][Full Text] [Related]
14. Development and validation of a prognostic immune-associated gene signature in clear cell renal cell carcinoma.
Shen C; Liu J; Wang J; Zhong X; Dong D; Yang X; Wang Y
Int Immunopharmacol; 2020 Apr; 81():106274. PubMed ID: 32044664
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of a gene signature in clear cell renal cell carcinoma.
Chen L; Luo Y; Wang G; Qian K; Qian G; Wu CL; Dan HC; Wang X; Xiao Y
J Cell Physiol; 2019 Jul; 234(7):10324-10335. PubMed ID: 30417359
[TBL] [Abstract][Full Text] [Related]
16. Autophagic Gene Polymorphisms in Liquid Biopsies and Outcome of Patients with Metastatic Clear Cell Renal Cell Carcinoma.
Santoni M; Piva F; De Giorgi U; Mosca A; Basso U; Santini D; Buti S; Lolli C; Terrone C; Maruzzo M; Iuliani M; Bersanelli M; Conti A; Mazzucchelli R; Montironi R; Burattini L; Berardi R
Anticancer Res; 2018 Oct; 38(10):5773-5782. PubMed ID: 30275199
[TBL] [Abstract][Full Text] [Related]
17. Identification of 9 key genes and small molecule drugs in clear cell renal cell carcinoma.
Luo Y; Shen D; Chen L; Wang G; Liu X; Qian K; Xiao Y; Wang X; Ju L
Aging (Albany NY); 2019 Aug; 11(16):6029-6052. PubMed ID: 31422942
[TBL] [Abstract][Full Text] [Related]
18. Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.
Wu P; Liu JL; Pei SM; Wu CP; Yang K; Wang SP; Wu S
BMC Cancer; 2018 Mar; 18(1):287. PubMed ID: 29534679
[TBL] [Abstract][Full Text] [Related]
19. GFOD1 and peejar are promising markers for clear-cell renal cell carcinoma disease progression.
Wu XR; Chen YH; Chen W; Kong W; Huang JW; Zhang J; Xue W; Liu DM; Huang YR
Oncotarget; 2016 Jun; 7(25):38004-38009. PubMed ID: 27191742
[TBL] [Abstract][Full Text] [Related]
20. Upregulated immune checkpoint HHLA2 in clear cell renal cell carcinoma: a novel prognostic biomarker and potential therapeutic target.
Chen D; Chen W; Xu Y; Zhu M; Xiao Y; Shen Y; Zhu S; Cao C; Xu X
J Med Genet; 2019 Jan; 56(1):43-49. PubMed ID: 29967134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]